Veterinary Medicines

CANIGEN DHPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION FOR DOGS

Authorised
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine distemper virus, strain Lederle, Live
Download as PDF

Product identification

Medicine name:
CANIGEN DHPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION FOR DOGS
Canigen DHPPi liofilizāts un šķīdinātājs suspensijas injekcijām pagatavošanai suņiem
Active substance:
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine distemper virus, strain Lederle, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine adenovirus 2, strain Manhattan, Live
    4.00
    log10 50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine parainfluenza virus, strain Manhattan, Live
    5.00
    log10 50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine parvovirus, strain Cornell 780916, Live
    5.00
    log10 50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine distemper virus, strain Lederle, Live
    3.00
    log10 50% tissue culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Latvia
Package description:
  • Cardboard box of 1 vial lyophilisate and 1 vial solvent
  • Plastic box of 100 vials lyophilisate and 100 vials solvent
  • Plastic box of 50 vials lyophilisate and 50 vials solvent
  • Plastic box of 25 vials lyophilisate and 25 vials solvent
  • Plastic box of 10 vials lyophilisate and 10 vials solvent
  • Plastic box of 5 vials lyophilisate and 5 vials solvent
  • Plastic box of 1 vial lyophilisate and 1 vial solvent
  • Cardboard box of 100 vials lyophilisate and 100 vials solvent
  • Cardboard box of 50 vials lyophilisate and 50 vials solvent
  • Cardboard box of 25 vials lyophilisate and 25 vials solvent
  • Cardboard boxof 10 vials lyophilisate and 10 vials solvent
  • Cardboard box of 5 vials lyophilisate and 5 vials solvent

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • Food And Veterinary Service
Authorisation number:
  • V/DCP/16/0014
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0297/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Latvian (PDF)
Published on: 26/09/2025
Download